Member Info for Parpaing

I certainly will. i first saw the appointment of Scott on Bloomberg, so a quick search found the items I posted. I'm all for anti-aging supplements etc. but I am hoping that Mr Maguire has seen the information I posted and that he has further, up-to-date information that "Dr. John v Capello" of Emergent Heath Group is a different Dr. Capello that lost his license as a doctor in Pennslyvania. I do not see how Scott has time to dabble in nutritional products as well as his other directorships in Healthcare Capital Partners Limited and Renal Services Ltd.

http://www.bloomberg.com/article/2015-01-05/aPtk1Ds2LuXU.html

I'm looking forward to Scott Maguire's reply to the question about why he is getting involved in a company selling an apparent Pump & Dump "Breakthrough new Health and Anti-aging secret". (See: http://www.timothysykes.com/2009/09/emges-ceo-responds-to-me...maybe...they-might-be-under-sec-investigation...maybe...weirdest-blog-post-ever/ ). and http://www.bizapedia.com/pa/DR-JOHN-V-CAPPELLO.html. Dr. John V. Cappello is a Pennsylvania Domestic Fictitious Name filed on August 7, 1984. Some might perceive that these products are nothing more than snake-oil and I am somewhat concerned that our esteemed CEO is getting involved in something that may harm the reputation of XBIO. please prove me wrong. Also see: http://www.vita-stim.com/ScientificSupport.html http://www.bizapedia.com/pa/DR-JOHN-V-CAPPELLO.html

conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions. To access the conference call, U.K.-based participants should call 0800 368 0649, and participants in all other locations should call +44 20 3059 8125. The participant password will be: Sciences. A telephone replay will be available for seven days following the call's conclusion. Replay dial-in numbers are as follows: United Kingdom 0121 260 4861; United States 866-268-1947; and all other locations + 44 121 260 4861. Please provide conference ID 3245500# when accessing the replay. In addition, the call will be webcast and available at the Investor Relations section of www.xeneticbio.com in the "Events and Presentations" tab.

http://www.bloomberg.com/article/2015-01-05/aPtk1Ds2LuXU.html

Glad to hear it. Lots of European businesses are really hurting due to the Russians retaliating with a ban on imports from sanctioning nations. However, we are not seeing lower prices for Camembert and Calvados, bearing in mind that sanctions have cost the EU 11.8 billion and the USA 972 million. Not exactly proportionate is it?

I was about to build my "sanction-USA" website this morning, as I believe that the US government may be holding back our entry into NASCAR. The stupid sanctions have hit European businesses worse than the intended effect on Russia.My family and I, will not be buying any Fatmacs, cocadopa, shale soil, peanut scrape, corn cats, Mushy bars, or smelly beans. I will not watch or buy US films, TV shows, adverts, cartoons or newscasts. We will not visit disney or the USA. See how you like that, Yanks! However, I'm willing to give them one last chance on Cousin Elmer's site.

Brilliant - I am getting some mileage off this story - many thanks!

I will be looking forward to this event - many thanks for the heads-up.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that it has completed enrollment of the second cohort of its Phase 2a dose-escalation study with ErepoXen® for the treatment of anemia in pre-dialysis chronic kidney disease patients. The patients enrolled in this cohort receive a biweekly injection of ErepoXen until hemoglobin levels reach therapeutic levels. The patients then receive injections of ErepoXen every 4 weeks during maintenance for a total trial time of 17 weeks. Eight of the 12 patients enrolled in this cohort have completed treatment. The data show that hemoglobin levels increased over time and rose into the therapeutic range. This compares with the first cohort of 12 patients, which showed an increase in hemoglobin levels over the course of the 17-week study but did not significantly penetrate the desired therapeutic level. In both cohorts ErepoXen was well tolerated and there were no significant adverse results deemed related to treatment. The study was conducted at 10 treatment sites, including eight in Australia and two in New Zealand. Professor Simon D Roger M.D., FRACP, Director of Renal Medicine, Gosford Hospital, New South Wales, Australia and principal investigator of the study, said, "The results achieved with ErepoXen in these chronic kidney disease patients confirm the efficacy of this biopharmaceutical and should lead to continued study of this compound. We have begun the process of preparing for the third cohort and determining the dose and interval for administration to be studied in this group. We are very encouraged about the potential for ErepoXen to treat these patients and look forward to providing additional data on the third cohort in 2015." "We have made tremendous progress with ErepoXen in the treatment of anemia in chronic kidney disease patients," said M. Scott Maguire, chief executive officer of Xenetic Biosciences. "We will provide the data generated in our study in Australia and New Zealand to the U.S. Food and Drug Administration to support a registration trial in the U.S. In addition, the work our license partners are doing in Russia and India provides us with additional confidence in our pathway seeking regulatory approval. The global market for anemia drugs exceeds $7 billion annually, and we believe ErepoXen will be a very attractive licensing asset in the U.S., Europe and Japan should data generated in current studies continue to be so compelling."

Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen(R) for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time. See XBIO website.

http://ir.xeneticbio.com/releasedetail.cfm?ReleaseID=888342

Just received an email Xenetic Biosciences CEO Delivers "2014 - The Year in Review" Update to Investors and Stakeholders. From Scott Maguire: We are excited about the many milestones we look to achieve during 2015. Among these are further results from the Phase 2 ErepoXen clinical trial being conducted in Australia and New Zealand. In addition, we plan to complete enabling studies for OncoHist in order to file an Investigational New Drug application with the FDA in AML, to initiate a Phase 2a study in 2015 in AML and possibly to initiate an additional Phase 2a study in another leukemia indication. We also plan to submit an orphan drug application in the U.S. and the EU for OncoHist in an additional hematology indication. One of our goals in 2014 was to list our common stock on the NASDAQ market. While we were not able to do so this past year, we remain committed to that goal as a priority for the Company; however, we cannot predict at this time when this may occur.

I think that an influential person should remind the London stock Exchange that the name Alternative Investment Market contains the word 'investment' which appears to be contrary to reality. Investment means the investing of money or capital in order to gain profitable returns, as interest, income, or appreciation in value. It does not mean funding stockbroker Christmas parties. AIM was designed to help small companies grow by obtaining capital in a less regulated market. Theoretically, Nomads are liable for damages from tolerating misdemeanors on behalf of their supervised companies, including the loss of reputational capital. However, this heavy reliance on Nomads has been criticised as creating a conflict of interest, since Nomads receive fees from the companies they purportedly supervise while, in practice, managing to avoid liability for market misconduct. Because AIM is an unregulated market segment, it escapes most of the mandatory provisions contained in European Union directives – as implemented in the UK – and other rules applicable to companies listed in the LSE. what we need is an Alternative Investor's Mandate where we can sue the clap out these so-called market makers. Yes, I am whinging about my portfolio only worth 25% of the capital I 'invested' into this crackpot market. The reputation of the London stock Exchange lacks credibility and they should do something about it. Particularly as my wife is being proved right when she said that i might as well have bought premium bonds. At least we could get our shekels back.

OK, must have missed it then. Its still good news though. Tried to buy some today but my broker doesn't deal with OTC. Many thanks, Dutch !

You must be able to see in the future then as it was only published by XBIO on Dec 4th and the ErepoXen news on the 2nd December 2014.

esearchers from Dana-Farber Cancer Institute (DFCI), one of the world’s leading cancer institutes, will be presenting the abstract, entitled “OncoHist™, an rh Histone 1.3 is cytotoxic to acute myeloid leukemia cells and results in altered downstream signaling (Suiyang Liu, Surender Kharbanda and Richard Stone).” The researchers conclude that their findings support the development of OncoHist alone and in combination with chemotherapy for the treatment of AML.

http://www.bloomberg.com/article/2014-12-04/abcjUmBTF.aA.html

Xenetic Biosciences has a substantial patent portfolio to rival any biotech company many times our size. This work results directly from our previous strategy focused on research. Now that we have transformed into a clinical development company we are well positioned for potentially monetizing our extensive intellectual property portfolio. We expect to add 13 additional patents over the next three months” said M. Scott Maguire chief executive officer of Xenetic Biosciences. “We are particularly pleased with our intellectual property position in Japan as those patent grants are typically difficult to secure. Our IP relates not only to our ‘bio-better’ EPO our lead candidate but also to improving availability of a number of protein-based drugs. We recently received an allowance for a U.S. patent relating to novel polysaccharide derivatives of granulocyte colony-stimulating factor (GCSF) and methods for producing such derivatives. The derivatives are useful for improving the stability pharmacokinetics and pharmacodynamics of GCSF. Our expectations are that we will have strong intellectual property protection for many years after our lead compounds have progressed through the U.S. regulatory process” Mr. Maguire added. More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=104390#.VHSwIslNq_0#ixzz3K6ZDD7Xs

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=104390#.VHSwIslNq_0